Licaminlimab

Request For Quotation
Licaminlimab Suppliers list
Company Name: ShangHai Biochempartner Co.,Ltd  
Tel: 177-54423994 17754423994
Email: 2853530910@QQ.com
Products Intro: Product Name:Licaminlimab
CAS:1688648-13-6
Purity:95% Package:100ug;500ug;1mg
Company Name: Wuhan Chemstan Biotechnology Co., Ltd.  
Tel: 027-65317797 15926423062
Email: 422450190@qq.com
Products Intro: Product Name:Licaminlimab
CAS:1688648-13-6
Purity:>95% Package:100ug;200ug;1mg
Company Name: Biolab Reagents  
Tel: 027-65279366 18108604356
Email: products@biolabreagent.com
Products Intro: Product Name:Research Grade Licaminlimab (DHB94409)
CAS:1688648-13-6
Purity:PAGE:>95% Package:100ug;1mg
Company Name: Atagenix Laboratories  
Tel: 027-87008169 17762441161
Email: info@atagenix.com
Products Intro: Product Name:Research Grade Licaminlimab
CAS:1688648-13-6
Purity:>95% Package:100ug
Company Name: AntibodySystem Laboratories SAS  
Tel: 33175446423
Email: support@antibodysystem.com
Products Intro: Product Name:Research Grade Licaminlimab (DHB94409)
Licaminlimab Basic information
Product Name:Licaminlimab
Synonyms:Licaminlimab;Research Grade Licaminlimab (DHB94409);Research Grade Licaminlimab
CAS:1688648-13-6
MF:
MW:0
EINECS:
Product Categories:
Mol File:Mol File
Licaminlimab Structure
Licaminlimab Chemical Properties
form Liquid
color Colorless to light yellow
Safety Information
MSDS Information
Licaminlimab Usage And Synthesis
UsesLicaminlimab (OCS-02) is a single-chain anti-TNF alpha antibody fragment. TNF alpha is an inflammatory cytokine produced by macrophages and monocytes during inflammation[1].
References[1] Shettle L, et al. Topical Anti-TNFα Agent Licaminlimab (OCS-02) Relieves Persistent Ocular Discomfort in Severe Dry Eye Disease: A Randomized Phase II Study. Clin Ophthalmol. 2022 Jul 6;16:2167-2177. DOI:10.2147/OPTH.S366836
Licaminlimab Preparation Products And Raw materials
Tag:Licaminlimab(1688648-13-6) Related Product Information
Minretumomab [inn] Docaravimab Lupartumab Ragifilimab Roledumab Tozorakimab Dezamizumab Rosmantuzumab Zamerovimab Adebrelimab